<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>APPROVED</status><version>v2</version><patient-age>82</patient-age><report-id>CZ-CELGENEUS-217-C5013-13013220</report-id><gender>male</gender><reactions><reaction>OESOPHAGEAL BLEEDING</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>CC-5013</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>ALLOPURINOL</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>OXYPHYLLIN</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>AMLODIN</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>10061275</indication><indication>10020907</indication><indication>10057097</indication><indication>10020775</indication></indications><patient-age>82</patient-age><outcomes><outcome>Life Threatening</outcome></outcomes><country>Czech Republic</country><geo/></meta><original><ichicsr lang="en" xmlns="">
  <ichicsrmessageheader lang="en">
    <messagetype>ichicsr</messagetype>
    <messageformatversion>2.1</messageformatversion>
    <messageformatrelease>2.0</messageformatrelease>
    <messagenumb>CEL000000000001289035</messagenumb>
    <messagesenderidentifier>CELGENE</messagesenderidentifier>
    <messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
    <messagedateformat>204</messagedateformat>
    <messagedate>20130125101126</messagedate>
  </ichicsrmessageheader>
  <safetyreport lang="en">
    <safetyreportversion lang="en">0</safetyreportversion>
    <safetyreportid lang="en">CZ-CELGENEUS-217-C5013-13013220</safetyreportid>
    <primarysourcecountry>CZ</primarysourcecountry>
    <occurcountry>CZ</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>2013-01-25</transmissiondate>
    <reporttype>2</reporttype>
    <serious code="1">Yes</serious>
    <seriousnesslifethreatening>1</seriousnesslifethreatening>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>2013-01-18</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>2013-01-18</receiptdate>
    <additionaldocument>2</additionaldocument>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb lang="en">CZ-CELGENE-217-C5013-13013220</companynumb>
    <medicallyconfirm>1</medicallyconfirm>
    <linkedreport>
      <linkreportnumb>CZ-CELGENE-217-C5013-12100435</linkreportnumb>
    </linkedreport>
    <primarysource>
      <reportergivename>David</reportergivename>
      <reporterfamilyname>Belada</reporterfamilyname>
      <reportercountry>CZ</reportercountry>
      <qualification code="1">Physician</qualification>
      <studyname lang="en">2008-003389-25#Phase 2 randomised study of lenalidomide vs. investigator's choice in MCL patients</studyname>
      <sponsorstudynumb>CC-5013-MCL-002</sponsorstudynumb>
      <observestudytype>1</observestudytype>
    </primarysource>
    <sender>
      <sendertype>1</sendertype>
      <senderorganization>CELGENEUS</senderorganization>
      <senderdepartment>Global Drug Safety</senderdepartment>
      <sendertitle>Manager</sendertitle>
      <sendergivename>Vivian</sendergivename>
      <senderfamilyname>Fonseca</senderfamilyname>
      <senderstreetaddress>300 Connell Drive, Suite 6000</senderstreetaddress>
      <sendercity>Berkeley Heights</sendercity>
      <senderstate>NJ</senderstate>
      <senderpostcode>07922</senderpostcode>
      <sendercountrycode>US</sendercountrycode>
      <sendertel>9082190331</sendertel>
      <senderfax>9086739115</senderfax>
      <senderemailaddress>vfonseca@celgene.com</senderemailaddress>
    </sender>
    <receiver>
      <receivertype>2</receivertype>
      <receiverorganization>FDAPM</receiverorganization>
      <receivergivename>Roger</receivergivename>
      <receivermiddlename>A</receivermiddlename>
      <receiverfamilyname>Goetsch</receiverfamilyname>
      <receivercountrycode>US</receivercountrycode>
    </receiver>
    <patient lang="en">
      <patientinitial>J-V</patientinitial>
      <patientinvestigationnumb>1221010</patientinvestigationnumb>
      <patientonsetage>82</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientweight>60</patientweight>
      <patientheight>160</patientheight>
      <patientsex code="1">Male</patientsex>
      <resultstestsprocedures lang="en">21Nov2012
-Gastroscopy: infiltration and stenosis of esophagus with bleeding and retention of salines</resultstestsprocedures>
      <patientdeath>
        <patientdeathdateformat>102</patientdeathdateformat>
        <patientdeathdate>20121129</patientdeathdate>
        <patientautopsyyesno>2</patientautopsyyesno>
        <patientdeathcause>
          <patientdeathreportmeddraversion>15.1</patientdeathreportmeddraversion>
          <patientdeathreport>10063378</patientdeathreport>
        </patientdeathcause>
      </patientdeath>
      <reaction>
        <primarysourcereaction lang="en">OESOPHAGEAL BLEEDING</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10071846</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10030172</reactionmeddrapt>
        <termhighlighted>3</termhighlighted>
        <reactionstartdateformat>102</reactionstartdateformat>
        <reactionstartdate>20121124</reactionstartdate>
        <reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
      </reaction>
      <test>
        <testdateformat>102</testdateformat>
        <testdate>20121121</testdate>
        <testname lang="en">GASTROSCOPY</testname>
      </test>
      <drug>
        <drugcharacterization code="1">suspsect</drugcharacterization>
        <medicinalproduct>CC-5013</medicinalproduct>
        <obtaindrugcountry>CZ</obtaindrugcountry>
        <drugauthorizationnumb>21-880</drugauthorizationnumb>
        <drugauthorizationcountry>US</drugauthorizationcountry>
        <drugauthorizationholder>Celgene Corporation</drugauthorizationholder>
        <drugdosageform normalized="capsule">Capsules</drugdosageform>
        <drugadministrationroute code="048">Oral</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10061275</drugindication>
        <actiondrug code="5">Unknown</actiondrug>
        <drugrecurreadministration code="3">Unknown</drugrecurreadministration>
        <activesubstance>
          <activesubstancename>LENALIDOMIDE</activesubstancename>
        </activesubstance>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10071846</drugreactionasses>
          <drugassessmentsource lang="en">1</drugassessmentsource>
          <drugassessmentmethod lang="en">EVCTM</drugassessmentmethod>
          <drugresult lang="en">1</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10071846</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not Provided</drugresult>
        </drugreactionrelatedness>
      </drug>
      <drug>
        <drugcharacterization code="2">concomitant</drugcharacterization>
        <medicinalproduct>ALLOPURINOL</medicinalproduct>
        <obtaindrugcountry>CZ</obtaindrugcountry>
        <drugstructuredosagenumb>100</drugstructuredosagenumb>
        <drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
        <drugdosagetext lang="en">100 Milligram</drugdosagetext>
        <drugdosageform normalized="unknown">Unknown</drugdosageform>
        <drugadministrationroute code="048">Oral</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10020907</drugindication>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2011</drugstartdate>
        <activesubstance>
          <activesubstancename>ALLOPURINOL</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization code="2">concomitant</drugcharacterization>
        <medicinalproduct>OXYPHYLLIN</medicinalproduct>
        <obtaindrugcountry>CZ</obtaindrugcountry>
        <drugstructuredosagenumb>100</drugstructuredosagenumb>
        <drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
        <drugseparatedosagenumb>2</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
        <drugdosagetext lang="en">200 Milligram</drugdosagetext>
        <drugdosageform normalized="unknown">Unknown</drugdosageform>
        <drugadministrationroute code="048">Oral</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10057097</drugindication>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2008</drugstartdate>
        <activesubstance>
          <activesubstancename>ETOFYLLINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization code="2">concomitant</drugcharacterization>
        <medicinalproduct>AMLODIN</medicinalproduct>
        <obtaindrugcountry>CZ</obtaindrugcountry>
        <drugstructuredosagenumb>2.5</drugstructuredosagenumb>
        <drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
        <drugdosagetext lang="en">2.5 Milligram</drugdosagetext>
        <drugdosageform normalized="unknown">Unknown</drugdosageform>
        <drugadministrationroute code="048">Oral</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10020775</drugindication>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2008</drugstartdate>
        <activesubstance>
          <activesubstancename>AMLODIPINE BESILATE</activesubstancename>
        </activesubstance>
      </drug>
      <summary lang="en">
        <narrativeincludeclinical>INVESTIGATOR SAE VERBATIM: <Semaphore x="3151990" class="MedDRA LLT" value="Oesophageal haemorrhage" score="1.00" ID="10030172">OESOPHAGEAL <Semaphore x="2015671" class="Disease or Finding" value="Hemorrhage" score="1.00" ID="C26791">BLEEDING</Semaphore></Semaphore><Semaphore x="1653729" class="AnatomicStructure" value="C-Circle" score="1.00" ID="C105650">CC </Semaphore>5013-MCL 002 (Czech Republic): A phase 2, multicenter, randomised, open label study to determine the efficacy of <Semaphore x="777068" class="Medicine" value="lenalidomide" score="0.49" ID="256986">lenalidomide </Semaphore>versus investigator's choice in patients with relapsed or <Semaphore x="2199427" class="Disease or Finding" value="Mantle Cell Lymphoma" score="1.00" ID="C4337">refractory mantle <Semaphore x="2141438" class="Procedure" value="Lymphoma Cell Count" score="1.00" ID="C74613">cell lymphoma</Semaphore></Semaphore>.<Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">Initial </Semaphore>information was received from the investigator on 18Jan2013 regarding an 82 years old male patient, 122-1010, who received study medication <Semaphore x="1653729" class="AnatomicStructure" value="C-Circle" score="1.00" ID="C105650">CC </Semaphore>5013 (<Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">therapy </Semaphore>dates unknown) for the <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>of <Semaphore x="2199427" class="Disease or Finding" value="Mantle Cell Lymphoma" score="1.00" ID="C4337">mantle <Semaphore x="2141438" class="Procedure" value="Lymphoma Cell Count" score="1.00" ID="C74613">cell lymphoma</Semaphore></Semaphore>. There were no data provided on medical history. Concomitant medication included <Semaphore x="949575" class="Medicine" value="Omeprazole" score="0.74" ID="273990">Omeprazole </Semaphore>for <Semaphore x="3004931" class="MedDRA LLT" value="Hiatus hernia" score="1.00" ID="10020028">oesophageal <Semaphore x="2022961" class="Disease or Finding" value="Hernia" score="1.00" ID="C34685">hernia </Semaphore></Semaphore>(starting 2011) <Semaphore x="77816" class="Medicine" value="Allopurinol" score="0.49" ID="269911">Allopurinol </Semaphore>for <Semaphore x="2038730" class="Disease or Finding" value="Hyperuricemia" score="1.00" ID="C3961">hyperuricemia </Semaphore><Semaphore x="2420563" class="Procedure" value="Preventive Intervention" score="1.00" ID="C15843">prophylaxis</Semaphore>, Amlodipin for <Semaphore x="1545159" class="AnatomicStructure" value="Artery" score="1.00" ID="C12372">arterial </Semaphore><Semaphore x="2038093" class="Disease or Finding" value="Hypertension" score="1.00" ID="C3117">hypertension </Semaphore>and Oxyphillin for unknown indication.On 24Nov2012 the patient presented <Semaphore x="3151990" class="MedDRA LLT" value="Oesophageal haemorrhage" score="1.00" ID="10030172">esophageal bleeding </Semaphore>(NCI <Semaphore x="1782929" class="Procedure" value="Circulating Tumor Cell Count" score="1.00" ID="C96593">CTC </Semaphore><Semaphore x="2027225" class="Procedure" value="Histopathologic Examination" score="1.00" ID="C18190">grade </Semaphore>4); the investigator considered the event life threatening. <Semaphore x="1968713" class="Procedure" value="Gastroscopy" score="1.00" ID="C16604">Gastroscopy </Semaphore>on 21Nov2012 showed infiltration and <Semaphore x="2584843" class="Disease or Finding" value="Stenosis" score="1.00" ID="C50754">stenosis </Semaphore>of <Semaphore x="1903437" class="AnatomicStructure" value="Esophagus" score="1.00" ID="C12389">esophagus </Semaphore>with <Semaphore x="2988829" class="MedDRA LLT" value="Haemorrhage" score="1.00" ID="10055798">bleeding </Semaphore>and retention of salines.The patient received <Semaphore x="949575" class="Medicine" value="Omeprazole" score="0.74" ID="273990">Omeprazole </Semaphore>iv as <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>for <Semaphore x="3151990" class="MedDRA LLT" value="Oesophageal haemorrhage" score="1.00" ID="10030172">esophageal <Semaphore x="2988727" class="MedDRA LLT" value="Haemorrhage prophylaxis" score="1.00" ID="10065667">bleeding</Semaphore></Semaphore>
    <Semaphore x="2988727" class="MedDRA LLT" value="Haemorrhage prophylaxis" score="1.00" ID="10065667">, <Semaphore x="885260" class="Medicine" value="Morphine" score="0.49" ID="280811">morphine </Semaphore>for <Semaphore x="2420563" class="Procedure" value="Preventive Intervention" score="1.00" ID="C15843">prophylaxis </Semaphore></Semaphore>of <Semaphore x="2463736" class="Disease or Finding" value="Respiratory Distress" score="1.00" ID="C27165">respiratory distress </Semaphore>and <Semaphore x="1283489" class="Medicine" value="Torecan" score="0.49" ID="249003">Torecan </Semaphore>as antiemetic.The patient died on 29Nov2012 due to unknown cause; the event <Semaphore x="3151990" class="MedDRA LLT" value="Oesophageal haemorrhage" score="1.00" ID="10030172">esophageal bleeding </Semaphore>was ongoing at <Semaphore x="1837270" class="Disease or Finding" value="Death" score="1.00" ID="C28554">death</Semaphore>. No autopsy has been performed.The investigator provided the following causality <Semaphore x="2397639" class="Procedure" value="Physical Examination" score="1.00" ID="C20989">assessment</Semaphore>:<Semaphore x="3151990" class="MedDRA LLT" value="Oesophageal haemorrhage" score="1.00" ID="10030172">Esophageal bleeding</Semaphore>: <Semaphore x="1653729" class="AnatomicStructure" value="C-Circle" score="1.00" ID="C105650">CC </Semaphore>5013 (not provided)Further information will be requested.This case is linked to MCN 217-C5013-12100435 (Staphylococcus <Semaphore x="3245054" class="MedDRA LLT" value="Sepsis" score="1.00" ID="10040047">sepsis</Semaphore>)</narrativeincludeclinical>
        <sendercomment lang="en">This 82 year old patient was diagnosed with life-threatening esophageal bleeding during the treatment with CC-5013 for relapsed or refractory Mantle cell lymphoma (treatment dates and time to onset not provided). The patient was taking concomitant Omeprasole for esophageal hernia. Three days before reported life-threatening bleeding a gastroscopy was done that showed infiltration and stenosis of oesophagus with bleeding. Treatment included proton-pump-inhibitors (Omeprasole), morphin and antiemetics. However, the patient died in five days, cause of death was not provided. Esophageal bleeding was ongoing at death. The investigator did not provide causality assesssment. While temporal relationship between therapy and OESOPHAGEAL BLEEDING suggest that a causal relationship cannot be excluded (possible), the case is missing critical information for a meaningful causality assessment. However, esophageal hernia could led to erosions and ulcers and could be considered as a contributory factor. Further information including CC-5013 therapy dates, full gastrointestinal history and risk factors (alcohol use, dietary), clinical symptoms with timing, stage of underlying disease, concomitant medications, including NSAIDs and thromboprophylaxis, diagnostic data will be requested.</sendercomment>
      </summary>
    </patient>
  </safetyreport>
</ichicsr></original></faers>